Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Heart Lung. 2013 Jul-Aug;42(4):257-61. doi: 10.1016/j.hrtlng.2012.12.008. Epub 2013 Jan 7.

Association of implantable defibrillator therapy risk with body mass index in systolic heart failure.

Author information

  • 1Cardiovascular Center, University of Michigan Health System, Ann Arbor, MI 48109-5853, USA.



To determine whether risk for implantable cardioverter-defibrillator (ICD) therapy varies by body mass index (BMI) in systolic heart failure (HF).


It is unknown whether obesity increases sudden death risk in patients with systolic HF.


Secondary analysis of patients with HF, left ventricular ejection fraction ≤0.40 and ICD (N = 464) was performed using Cox regression modeling to assess risk for first delivered ICD therapy, with patients grouped by BMI (kg/m(2)): normal (18.5 to <25), overweight (25 to <30), and obese (≥30).


Overweight patients, compared with patients with normal BMI, had greater adjusted risk for first ICD therapy (HR 1.66; 95% CI 1.02-2.71; P = 0.04), whereas obese BMI was not associated with risk for first ICD therapy.


There was an inverted U-shaped relationship between BMI and risk for first ICD therapy among systolic HF patients, with highest risk in overweight BMI.

Copyright © 2013 Elsevier Inc. All rights reserved.


ACE; ARB; BMI; Body mass index; HF; Heart failure; ICD; Implantable cardioverter-defibrillator; Risk stratification; UMHS; University of Michigan Health System; VAD; aldosterone receptor blocker; angiotensin converting enzyme; body mass index; heart failure; implantable cardioverter-defibrillator; ventricular assist device

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk